Your browser doesn't support javascript.
loading
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.
Schludi, Belinda; Giugliano, Robert P; Sabatine, Marc S; Raal, Frederick J; Teramoto, Tamio; Koren, Michael J; Stein, Evan A; Wang, Huei; Monsalvo, Maria Laura.
Afiliação
  • Schludi B; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA. Electronic address: bschludi@amgen.com.
  • Giugliano RP; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Sabatine MS; TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Raal FJ; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Teramoto T; Teikyo Academic Research Center, Teikyo University, Tokyo, Japan.
  • Koren MJ; Jacksonville Center for Clinical Research, Jacksonville, FL, USA.
  • Stein EA; Metabolic & Atherosclerosis Research Center, Cincinnati, OH, USA.
  • Wang H; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
  • Monsalvo ML; Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
J Clin Lipidol ; 16(4): 538-543, 2022.
Article em En | MEDLINE | ID: mdl-35760720
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Anticolesterolemiantes Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article